NASDAQ: TMCITreace Medical Concepts Inc Stock
$11.27-0.13 (-1.14%)
Updated Apr 18, 2024
TMCI Price
$11.27
Fair Value Price
N/A
Market Cap
$695.98M
52 Week Low
$5.27
52 Week High
$27.70
P/E
-13.91x
P/B
5.05x
P/S
4.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$187.12M
Earnings
-$49.53M
Gross Margin
81.2%
Operating Margin
-23.71%
Profit Margin
-26.5%
Debt to Equity
0.83
Operating Cash Flow
-$35M
Beta
1.29
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TMCI Overview
Treace Medical Concepts Incorporated manufactures and sells medical devices to foot and ankle surgeons in the U.S. Its Lapiplasty procedure allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides the Lapiplasty Mini-Incision precision system. Treace Medical Concepts was founded in 2013 and is headquartered in Ponte Vedra Beach, FL.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TMCI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TMCI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TMCI is poor value based on its book value relative to its share price (5.05x), compared to the US Medical Devices industry average (3.63x)
P/B vs Industry Valuation
TMCI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TMCI due diligence checks available for Premium users.
Be the first to know about important TMCI news, forecast changes, insider trades & much more!
TMCI News
Valuation
TMCI fair value
Fair Value of TMCI stock based on Discounted Cash Flow (DCF)
Price
$11.27
Fair Value
-$0.12
Undervalued by
9,464.74%
TMCI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TMCI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13.91x
Industry
28.61x
Market
41.33x
TMCI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.05x
Industry
3.63x
TMCI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TMCI's financial health
Profit margin
Revenue
$62.2M
Net Income
-$6.3M
Profit Margin
-10.1%
TMCI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TMCI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$251.9M
Liabilities
$114.0M
Debt to equity
0.83
TMCI's short-term assets ($198.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TMCI's short-term assets ($198.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TMCI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$532.0k
Investing
$5.0M
Financing
$165.0k
TMCI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TMCI vs Medical Device Stocks
Treace Medical Concepts Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.